Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit

This publication has 22 references indexed in Scilit:

• Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene
  Blood, 2002
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
  Science, 2001
• Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
  New England Journal of Medicine, 2001
• Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571
  Oncogene, 2000
• Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis
  Experimental Hematology, 2000
• Indolinone Derivatives Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast Cells
  Journal of Investigative Dermatology, 2000
• Activating c-kit Gene Mutations in Human Germ Cell Tumors
  The American Journal of Pathology, 1999
• Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
  Science, 1998
• Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces Apoptosis
  Blood Cells, Molecules, and Diseases, 1997
• Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm
  Nature Genetics, 1996